Ardelyx (ARDX) Stock Forecast, Price & News

Ardelyx (NASDAQ:ARDX) Frequently Asked Questions

Is Ardelyx a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Ardelyx stock.
View analyst ratings for Ardelyx or view top-rated stocks.

Are investors shorting Ardelyx?

Ardelyx saw a increase in short interest in April. As of April 30th, there was short interest totaling 11,540,000 shares, an increase of 20.0% from the April 15th total of 9,620,000 shares. Based on an average daily volume of 3,620,000 shares, the days-to-cover ratio is currently 3.2 days.
View Ardelyx's Short Interest.

When is Ardelyx's next earnings date?

Ardelyx is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022.
View our earnings forecast for Ardelyx.

How were Ardelyx's earnings last quarter?

Ardelyx, Inc. (NASDAQ:ARDX) announced its quarterly earnings results on Thursday, May, 5th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.01. Ardelyx had a negative net margin of 3,843.36% and a negative trailing twelve-month return on equity of 177.07%. During the same quarter last year, the business posted ($0.34) earnings per share.
View Ardelyx's earnings history.

What price target have analysts set for ARDX?

7 equities research analysts have issued 12-month price objectives for Ardelyx's stock. Their forecasts range from $1.00 to $13.00. On average, they anticipate Ardelyx's share price to reach $5.24 in the next year. This suggests a possible upside of 702.6% from the stock's current price.
View analysts' price targets for Ardelyx or view top-rated stocks among Wall Street analysts.

Who are Ardelyx's key executives?

Ardelyx's management team includes the following people:

• Mr. Michael G. Raab, Pres, CEO & Director (Age 57, Pay $947.66k) (LinkedIn Profile)
• Mr. Justin A. Renz CPA, M.S.T., MBA, MST, CFO & Treasurer (Age 50, Pay $394.74k)
• Ms. Susan Rodriguez, Chief Commercial Officer (Age 58, Pay $588.96k)
• Mr. Robert Felsch, Sr. VP of Fin. & Chief Accounting Officer
• Ms. Elizabeth A. Grammer, Chief Legal & Admin. Officer and Sec. (Age 58) (LinkedIn Profile)
• Ms. Kimia Keshtbod, Mang. of Corp. Communications & Investor Relations
• Mr. David P. Rosenbaum, Chief Devel. Officer (Age 61) (LinkedIn Profile)
• Mr. Robert C. Blanks, Chief Regulatory Affairs & Quality Assurance Officer (Age 62) (LinkedIn Profile)
• Ms. Karen Harrigan, Sr. Director Market Devel.
• Dan Pavicich, Sr. Director of Market Devel.

Who are some of Ardelyx's key competitors?

Some companies that are related to Ardelyx include Tyra Biosciences (TYRA), DiaMedica Therapeutics (DMCAF), BioXcel Therapeutics (BTAI), Heron Therapeutics (HRTX), Nuvalent (NUVL), Rigel Pharmaceuticals (RIGL), Gelesis (GLS), Repare Therapeutics (RPTX), ALX Oncology (ALXO), COMPASS Pathways (CMPS), Rallybio (RLYB), PyroGenesis Canada (PYR), Arbutus Biopharma (ABUS), Fulcrum Therapeutics (FULC) and Edgewise Therapeutics (EWTX).
View all of ARDX's competitors.

What other stocks do shareholders of Ardelyx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ardelyx investors own include Micron Technology (MU), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP), TherapeuticsMD (TXMD) and Advanced Micro Devices (AMD).

What is Ardelyx's stock symbol?

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

Who are Ardelyx's major shareholders?

Ardelyx's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.94%), Great Point Partners LLC (3.29%), Vanguard Group Inc. (2.72%), AIGH Capital Management LLC (2.15%), State Street Corp (1.47%) and Pekin Hardy Strauss Inc. (1.20%). Company insiders that own Ardelyx stock include David M Mott, David P Rosenbaum, Elizabeth A Grammer, Forest Baskett, Jeffrey W Jacobs, Jeffrey W Jacobs, Justin A Renz, Michael Raab, Robert Blanks, Scott D Sandell and Susan Rodriguez.
View institutional ownership trends for Ardelyx.

Which major investors are selling Ardelyx stock?

ARDX stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Vanguard Group Inc., Goldman Sachs Group Inc., Group One Trading L.P., Quantbot Technologies LP, Dimensional Fund Advisors LP, Magnus Financial Group LLC, and Simplex Trading LLC. Company insiders that have sold Ardelyx company stock in the last year include David P Rosenbaum, Elizabeth A Grammer, Jeffrey W Jacobs, Michael Raab, Robert Blanks, and Scott D Sandell.
View insider buying and selling activity for Ardelyx or view top insider-selling stocks.

Which major investors are buying Ardelyx stock?

ARDX stock was bought by a variety of institutional investors in the last quarter, including Great Point Partners LLC, AIGH Capital Management LLC, GSA Capital Partners LLP, Bank of New York Mellon Corp, Pekin Hardy Strauss Inc., Worth Venture Partners LLC, State Street Corp, and Orchard Capital Managment LLC.
View insider buying and selling activity for Ardelyx or or view top insider-buying stocks.

How do I buy shares of Ardelyx?

Shares of ARDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ardelyx's stock price today?

One share of ARDX stock can currently be purchased for approximately $0.65.

How much money does Ardelyx make?

Ardelyx has a market capitalization of $94.45 million and generates $10.10 million in revenue each year. The biopharmaceutical company earns $-158.16 million in net income (profit) each year or ($1.39) on an earnings per share basis.

How many employees does Ardelyx have?

Ardelyx employs 86 workers across the globe.

What is Ardelyx's official website?

The official website for Ardelyx is www.ardelyx.com.

How can I contact Ardelyx?

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company can be reached via phone at (510) 745-1700, via email at [email protected], or via fax at 510-745-0493.